Phase 2 Interstitial Lung Disease Trial, Recruiting NCT06471556 Sponsor: Assistance Publique - Hôpitaux de Paris Condition: Interstitial Lung Disease
Back to Interstitial Lung Disease

Phase 2 Interstitial Lung Disease Trial, Recruiting

NCT06471556
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Babies under 12 months of age
  • Babies who have been diagnosed with a condition called Neuroendocrine Cell Hyperplasia of Infancy (NEHI), confirmed either by a clinical scoring tool (called the Liptzin score) combined with a specific chest scan pattern, or by a clinical assessment, chest scan, and a lung tissue sample showing an increased number of certain specialised cells in the airways
  • Babies who need supplemental oxygen (whether awake, asleep, or both), based on standard children's medical guidelines
  • Babies who are being cared for at one of the RespiRare participating medical centres
  • Babies whose parent(s) or legal guardian(s) have given written consent for participation before the trial begins

Who may not be able to join:

  • Babies where another cause for their lung condition has been identified through blood tests, genetic testing, airway fluid sampling, or a lung tissue sample
  • Babies who have previously received intravenous methylprednisolone (a type of steroid medication given through a drip) at any point
  • Babies who have diabetes
  • Babies who have high blood pressure that is not well controlled
  • Babies who do not have health insurance coverage
  • Babies who currently have an active infection
  • Babies who have received a live attenuated vaccine (a specific type of vaccine) within the past two weeks
  • Babies who are already on long-term treatment with Azithromycin and/or Hydroxychloroquine (specific medications)
  • Babies who are already taking part in another interventional clinical study or trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Nadia NATHAN, Assistance Publique - Hôpitaux de Paris

Phone: 00 33 1 44 73 66 18

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
30 June 2025
Est. completion
28 February 2029

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Number of children still requiring oxygen therapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov